-
Product Insights
NewLikelihood of Approval Analysis for Duchenne Muscular Dystrophy
Overview How likely is it that the drugs in Duchenne Muscular Dystrophy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Duchenne Muscular Dystrophy Overview Duchenne muscular dystrophy (DMD) is a genetic...
-
Product Insights
NewLikelihood of Approval Analysis for Spinal Muscular Atrophy (SMA)
Overview How likely is it that the drugs in Spinal Muscular Atrophy (SMA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brogidirsen in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brogidirsen in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brogidirsen in Duchenne Muscular Dystrophy Drug Details: Brogidirsen (NS-089) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vesleteplirsen in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vesleteplirsen in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vesleteplirsen in Duchenne Muscular Dystrophy Drug Details: Vesleteplirsen is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vamorolone in Becker Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vamorolone in Becker Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vamorolone in Becker Muscular Dystrophy Drug Details: Vamorolone (Agamree) acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifetroban in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifetroban in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifetroban in Duchenne Muscular Dystrophy Drug Details: Ifetroban (Vasculan, Boxaban, Hepatoren,Portaban)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-1102 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS 107248)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-065 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-065 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-065 in Duchenne Muscular Dystrophy Drug Details: KER-065 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Duchenne Muscular Dystrophy Drug Details: MP-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luminol Monosodium in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luminol Monosodium in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luminol Monosodium in Duchenne Muscular Dystrophy Drug Details: MP-1032...